March 2010  |  Philadelphia, PA

Mufson Howe Hunter & Company is pleased to announce that Bioreclemation has completed a recapitalization and has received the placement of growth capital from Lineage Capital, LLC.

Bioreclamation is an industry leading manufacturer, processer, marketer and distributor of control matrix material used by biotechnology and pharmaceutical companies in preclinical and clinical development.  The Company markets to drug developers, research materials from over 32 different animal species, healthy human materials and disease-state human products covering nine disease categories.  Bioreclamation’s customer base includes all of the major biotechnology and pharmaceutical firms domestically and abroad.

Mufson Howe Hunter & Company was hired as the Company’s exclusive financial advisor to explore various options for financing the on-going growth of the Company as well as to provide a significant liquidity event to the Company’s founding shareholders. This engagement underscores MHH’s commitment to partnering with leading industrials and manufacturing companies.